{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T21:38:34Z","timestamp":1771882714157,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Prim. Care Respir. Med."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This review explores the effect of tiotropium Respimat\u00ae add-on therapy on asthma exacerbations and worsenings, adverse events (AEs) related to exacerbations and symptoms and any effects on seasonality across the 10 UniTinA-asthma\u00ae clinical trials comprising over 6000 patients. When added on to inhaled corticosteroids\u2009\u00b1\u2009additional therapies, tiotropium significantly reduced the risk of exacerbations and worsenings in adults with symptomatic severe asthma and provided a non-significant improvement in worsenings in adults with symptomatic moderate and mild asthma, which was significant for patients with moderate asthma receiving tiotropium 2.5\u2009\u00b5g once daily vs. placebo. Trials in paediatric patients were not powered to assess exacerbations or worsenings, but when AEs related to asthma exacerbations and symptoms were grouped into a composite endpoint and pooled, tiotropium improved outcomes vs. placebo (rate ratio 0.76; 95% confidence interval 0.63, 0.93). The reduction in exacerbations with tiotropium is apparent across all patients during the observed seasonal peaks of these events.<\/jats:p>","DOI":"10.1038\/s41533-020-00193-w","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T10:03:50Z","timestamp":1598868230000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Asthma exacerbations and worsenings in patients aged 1\u201375 years with add-on tiotropium treatment"],"prefix":"10.1038","volume":"30","author":[{"given":"J.","family":"Mark FitzGerald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eckard","family":"Hamelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7705-7927","authenticated-orcid":false,"given":"Huib A. M.","family":"Kerstjens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Buhl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,31]]},"reference":[{"key":"193_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41533-017-0014-1","volume":"27","author":"ID Pavord","year":"2017","unstructured":"Pavord, I. D. et al. The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting beta2-agonists in the United Kingdom: a cross-sectional analysis. NPJ Prim. Care Respir. Med. 27, 17 (2017).","journal-title":"NPJ Prim. Care Respir. Med."},{"key":"193_CR2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1183\/16000617.00001615","volume":"24","author":"AI Papaioannou","year":"2015","unstructured":"Papaioannou, A. I. et al. Control of asthma in real life: still a valuable goal? Eur. Respir. Rev. 24, 361\u2013369 (2015).","journal-title":"Eur. Respir. Rev."},{"key":"193_CR3","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention (2020 report). https:\/\/ginasthma.org\/wp-content\/uploads\/2020\/04\/GINA-2020-full-report_-final-_wms.pdf (2020)."},{"key":"193_CR4","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.jaci.2009.05.010","volume":"124","author":"CA Camargo Jr.","year":"2009","unstructured":"Camargo, C. A. Jr., Rachelefsky, G. & Schatz, M. Managing asthma exacerbations in the emergency department: summary of the National Asthma Education and Prevention Program Expert Panel Report 3 guidelines for the management of asthma exacerbations. J. Allergy Clin. Immunol. 124, S5\u2013S14 (2009).","journal-title":"J. Allergy Clin. Immunol."},{"key":"193_CR5","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1056\/NEJMoa1714257","volume":"378","author":"T McKeever","year":"2018","unstructured":"McKeever, T. et al. Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations. N. Engl. J. Med. 378, 902\u2013910 (2018).","journal-title":"N. Engl. J. Med."},{"key":"193_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/ACI.0b013e3283466f45","volume":"11","author":"RJ Loymans","year":"2011","unstructured":"Loymans, R. J., Ter Riet, G. & Sterk, P. J. Definitions of asthma exacerbations. Curr. Opin. Allergy Clin. Immunol. 11, 181\u2013186 (2011).","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"193_CR7","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S2213-2600(17)30212-6","volume":"5","author":"JM FitzGerald","year":"2017","unstructured":"FitzGerald, J. M. & Sadatsafavi, M. Improving precision in the prediction of asthma exacerbations. Lancet Respir. Med. 5, 539\u2013540 (2017).","journal-title":"Lancet Respir. Med."},{"key":"193_CR8","first-page":"OA3258","volume":"46","author":"A Fuhlbrigge","year":"2015","unstructured":"Fuhlbrigge, A., Bengtsson, T., Peterson, S., Jauhiainen, A. & Fageras, M. CompEx\u2014a novel composite asthma exacerbation endpoint. Eur. Respir. J. 46, OA3258 (2015).","journal-title":"Eur. Respir. J."},{"key":"193_CR9","doi-asserted-by":"publisher","first-page":"1B","DOI":"10.1155\/2008\/973062","volume":"15","author":"M Balter","year":"2008","unstructured":"Balter, M. et al. Asthma worsenings: approaches to prevention and management from the Asthma Worsenings Working Group. Can. Respir. J. 15, 1B\u201319B (2008).","journal-title":"Can. Respir. J."},{"key":"193_CR10","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1016\/j.jaci.2011.12.983","volume":"129","author":"A Fuhlbrigge","year":"2012","unstructured":"Fuhlbrigge, A. et al. Asthma outcomes: exacerbations. J. Allergy Clin. Immunol. 129, S34\u2013S48 (2012).","journal-title":"J. Allergy Clin. Immunol."},{"key":"193_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1365-2222.2008.03157.x","volume":"39","author":"RH Dougherty","year":"2009","unstructured":"Dougherty, R. H. & Fahy, J. V. Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype. Clin. Exp. Allergy 39, 193\u2013202 (2009).","journal-title":"Clin. Exp. Allergy"},{"key":"193_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/thx.2010.156760","volume":"66","author":"JM FitzGerald","year":"2011","unstructured":"FitzGerald, J. M. Targeting lung attacks. Thorax 66, 365\u2013366 (2011).","journal-title":"Thorax"},{"key":"193_CR13","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.rmed.2015.01.012","volume":"109","author":"JC Virchow","year":"2015","unstructured":"Virchow, J. C. et al. Defining moderate asthma exacerbations in clinical trials based on ATS\/ERS joint statement. Respir. Med. 109, 547\u2013556 (2015).","journal-title":"Respir. Med."},{"key":"193_CR14","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jaci.2016.01.011","volume":"138","author":"E Hamelmann","year":"2016","unstructured":"Hamelmann, E. et al. Tiotropium add-on therapy in adolescents with moderate asthma: a 1-year randomized controlled trial. J. Allergy Clin. Immunol. 138, 441\u2013450.e448 (2016).","journal-title":"J. Allergy Clin. Immunol."},{"key":"193_CR15","doi-asserted-by":"publisher","first-page":"1601100","DOI":"10.1183\/13993003.01100-2016","volume":"49","author":"E Hamelmann","year":"2017","unstructured":"Hamelmann, E. et al. A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma. Eur. Respir. J. 49, 1601100 (2017).","journal-title":"Eur. Respir. J."},{"key":"193_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S2213-2600(18)30012-2","volume":"6","author":"EJLE Vrijlandt","year":"2018","unstructured":"Vrijlandt, E. J. L. E. et al. Safety and efficacy of tiotropium in children aged 1\u20135 years with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trial. Lancet Respir. Med. 6, 127\u2013137 (2018).","journal-title":"Lancet Respir. Med."},{"key":"193_CR17","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/j.jaip.2018.04.032","volume":"6","author":"C Vogelberg","year":"2018","unstructured":"Vogelberg, C. et al. Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma. J. Allergy Clin. Immunol. Pract. 6, 2160\u20132162.e9 (2018).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"193_CR18","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.jaci.2017.01.014","volume":"140","author":"SJ Szefler","year":"2017","unstructured":"Szefler, S. J. et al. A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma. J. Allergy Clin. Immunol. 140, 1277\u20131287 (2017).","journal-title":"J. Allergy Clin. Immunol."},{"key":"193_CR19","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1208606","volume":"367","author":"HA Kerstjens","year":"2012","unstructured":"Kerstjens, H. A. et al. Tiotropium in asthma poorly controlled with standard combination therapy. N. Engl. J. Med. 367, 1198\u20131207 (2012).","journal-title":"N. Engl. J. Med."},{"key":"193_CR20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S2213-2600(15)00031-4","volume":"3","author":"HA Kerstjens","year":"2015","unstructured":"Kerstjens, H. A. et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respir. Med. 3, 367\u2013376 (2015).","journal-title":"Lancet Respir. Med."},{"key":"193_CR21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaip.2015.08.017","volume":"4","author":"P Paggiaro","year":"2016","unstructured":"Paggiaro, P. et al. The effect of tiotropium in symptomatic asthma despite low- to medium-dose inhaled corticosteroids: a randomized controlled trial. J. Allergy Clin. Immunol. Pract. 4, 104\u2013113.e2 (2016).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"193_CR22","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/jama.2018.2757","volume":"319","author":"DM Sobieraj","year":"2018","unstructured":"Sobieraj, D. M. et al. Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma: a systematic review and meta-analysis. JAMA 319, 1473\u20131484 (2018).","journal-title":"JAMA"},{"key":"193_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12931-020-1282-9","volume":"21","author":"C Vogelberg","year":"2020","unstructured":"Vogelberg, C. et al. A comparison of tiotropium, long-acting \u03b22-agonists and leukotriene receptor antagonists on lung function and exacerbations in paediatric patients with asthma. Respir. Res. 21, 19 (2020).","journal-title":"Respir. Res."},{"key":"193_CR24","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.jaci.2011.07.014","volume":"128","author":"A Thomas","year":"2011","unstructured":"Thomas, A., Lemanske, R. F. Jr & Jackson, D. J. Approaches to stepping up and stepping down care in asthmatic patients. J. Allergy Clin. Immunol. 128, 915\u2013924 (2011).","journal-title":"J. Allergy Clin. Immunol."},{"key":"193_CR25","unstructured":"Boehringer Ingelheim Limited. Spiriva Respimat 2.5 microgram, inhalation solution. https:\/\/www.medicines.org.uk\/emc\/product\/407\/smpc (2018)."},{"key":"193_CR26","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. SPIRIVA\u00ae RESPIMAT\u00ae (tiotropium bromide) inhalation spray, for oral inhalation. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021936s007lbl.pdf (2019)."},{"key":"193_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaci.2013.10.026","volume":"133","author":"MD Cabana","year":"2014","unstructured":"Cabana, M. D., Kunselman, S. J., Nyenhuis, S. M. & Wechsler, M. E. Researching asthma across the ages: insights from the National Heart, Lung, and Blood Institute\u2019s Asthma Network. J. Allergy Clin. Immunol. 133, 27\u201333 (2014).","journal-title":"J. Allergy Clin. Immunol."},{"key":"193_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1542\/peds.113.1.87","volume":"113","author":"MJ Coffey","year":"2004","unstructured":"Coffey, M. J., Wilfond, B. & Ross, L. F. Ethical assessment of clinical asthma trials including children subjects. Pediatrics 113, 87\u201394 (2004).","journal-title":"Pediatrics"},{"key":"193_CR29","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1002\/ppul.24035","volume":"53","author":"S Szefler","year":"2018","unstructured":"Szefler, S. et al. Improvements in reporting of asthma exacerbations in efficacy and safety data with tiotropium add-on therapy in pediatric patients. Pediatr. Pulmonol. 53, S103\u2013S104 (2018).","journal-title":"Pediatr. Pulmonol."},{"key":"193_CR30","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1016\/j.jaci.2017.01.028","volume":"139","author":"TL Staton","year":"2017","unstructured":"Staton, T. L. et al. Seasonal variability of severe asthma exacerbations and clinical benefit from lebrikizumab. J. Allergy Clin. Immunol. 139, 1682\u20131684.e3 (2017).","journal-title":"J. Allergy Clin. Immunol."},{"key":"193_CR31","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1136\/thx.2005.045161","volume":"61","author":"NW Johnston","year":"2006","unstructured":"Johnston, N. W. & Sears, M. R. Asthma exacerbations. 1: Epidemiology. Thorax 61, 722\u2013728 (2006).","journal-title":"Thorax"},{"key":"193_CR32","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2500\/aap.2018.39.4162","volume":"39","author":"L DuBuske","year":"2018","unstructured":"DuBuske, L., Newbold, P., Wu, Y. & Trudo, F. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab. Allergy Asthma Proc. 39, 345\u2013349 (2018).","journal-title":"Allergy Asthma Proc."},{"key":"193_CR33","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jaci.2008.08.003","volume":"122","author":"MR Sears","year":"2008","unstructured":"Sears, M. R. Epidemiology of asthma exacerbations. J. Allergy Clin. Immunol. 122, 662\u2013668 (2008).","journal-title":"J. Allergy Clin. Immunol."},{"key":"193_CR34","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1513\/pats.200706-064TH","volume":"4","author":"NW Johnston","year":"2007","unstructured":"Johnston, N. W. The similarities and differences of epidemic cycles of chronic obstructive pulmonary disease and asthma exacerbations. Proc. Am. Thorac. Soc. 4, 591\u2013596 (2007).","journal-title":"Proc. Am. Thorac. Soc."},{"key":"193_CR35","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.jaci.2014.12.1942","volume":"135","author":"SJ Teach","year":"2015","unstructured":"Teach, S. J. et al. Seasonal risk factors for asthma exacerbations among inner-city children. J. Allergy Clin. Immunol. 135, 1465\u20131473.e5 (2015).","journal-title":"J. Allergy Clin. Immunol."},{"key":"193_CR36","unstructured":"ClinicalTrials.gov. Efficacy and safety of 2 doses of tiotropium via Respimat in adult patients with mild persistent asthma. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01316380?term=NCT01316380&rank=1 (2011)."},{"key":"193_CR37","unstructured":"ClinicalTrials.gov. Evaluation of tiotropium 2.5 and 5 mcg once daily delivered via the Respimat\u00ae inhaler compared to placebo and salmeterol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (50 mcg twice daily) in patient with moderate persistent asthma I. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01172808?term=NCT01172808&rank=1 (2010)."},{"key":"193_CR38","first-page":"S102","volume":"52","author":"E Hamelmann","year":"2017","unstructured":"Hamelmann, E. et al. Once-daily tiotropium Respimat add-on therapy improves lung function in patients aged 6\u201317 years with severe symptomatic asthma. Pediatr. Pulmonol. 52, S102 (2017).","journal-title":"Pediatr. Pulmonol."},{"key":"193_CR39","unstructured":"International Conference on Harmonisation. Introductory guide for Standardised MedDRA Queries (SMQs) Version 20.0. https:\/\/www.meddra.org\/sites\/default\/files\/guidance\/file\/smq_intguide_20_0_english.pdf (2017)."},{"key":"193_CR40","first-page":"A122","volume":"73","author":"S Goldstein","year":"2018","unstructured":"Goldstein, S. et al. P45 effect of tiotropium Respimat\u00ae on seasonal asthma worsening in paediatric patients. Thorax 73, A122\u2013A123 (2018).","journal-title":"Thorax"},{"key":"193_CR41","doi-asserted-by":"publisher","first-page":"1801824","DOI":"10.1183\/13993003.01824-2018","volume":"53","author":"C Vogelberg","year":"2019","unstructured":"Vogelberg, C. et al. Tiotropium add-on therapy is safe and reduces seasonal worsening in paediatric asthma patients. Eur. Respir. J. 53, 1801824 (2019).","journal-title":"Eur. Respir. J."},{"key":"193_CR42","unstructured":"ClinicalTrials.gov. Evaluation of tiotropium 5 \u00b5g\/day delivered via the Respimat\u00ae inhaler over 48 weeks in patients with severe persistent asthma on top of usual care (study I). https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00772538?term=NCT00772538&rank=1 (2008)."},{"key":"193_CR43","unstructured":"ClinicalTrials.gov. Efficacy and safety of 2 doses of tiotropium Respimat compared to placebo in adolescents with severe persistent asthma. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01277523 (2011)."},{"key":"193_CR44","unstructured":"ClinicalTrials.gov. Efficacy and safety of 2 doses of tiotropium via Respimat compared to placebo in adolescents with moderate persistent asthma. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01257230 (2010)."},{"key":"193_CR45","unstructured":"ClinicalTrials.gov. Efficacy and safety of 2 doses of tiotropium Respimat\u00ae compared to placebo in children with severe persistent asthma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01634152?term=nct01634152&rank=1 (2012)."},{"key":"193_CR46","unstructured":"ClinicalTrials.gov. Efficacy and safety of 2 doses of tiotropium Respimat\u00ae compared to placebo in children with moderate persistent asthma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01634139?term=01634139&rank=1 (2012)."},{"key":"193_CR47","unstructured":"ClinicalTrials.gov. Evaluation of tiotropium 2.5 and 5 mcg once daily delivered via the Respimat\u00ae inhaler compared to placebo in 1 to 5 year old patients with persistent asthma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01634113?term=nct01634113&rank=1 (2012)."},{"key":"193_CR48","doi-asserted-by":"publisher","first-page":"1900964","DOI":"10.1183\/13993003.00964-2019","volume":"55","author":"JM FitzGerald","year":"2020","unstructured":"FitzGerald, J. M. et al. Tiotropium add-on therapy reduces seasonal peaks of asthma worsening in adults with symptomatic severe asthma. Eur. Respir. J. 55, 1900964 (2020).","journal-title":"Eur. Respir. J."}],"container-title":["npj Primary Care Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41533-020-00193-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41533-020-00193-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41533-020-00193-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T03:23:57Z","timestamp":1670297037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41533-020-00193-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,31]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["193"],"URL":"https:\/\/doi.org\/10.1038\/s41533-020-00193-w","relation":{},"ISSN":["2055-1010"],"issn-type":[{"value":"2055-1010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,31]]},"assertion":[{"value":"4 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.M.F. reports grants from Boehringer Ingelheim during the conduct of the study; personal fees and grants from Boehringer Ingelheim, AstraZeneca, Novartis, Sanofi-Regeneron, Circassia and Teva; and grants from GlaxoSmithKline outside the submitted work. E.H. has nothing to disclose. H.A.M.K. reports an unrestricted research grant, and fees for participation in advisory boards from Boehringer Ingelheim, Novartis and GlaxoSmithKline. He also reports fees for advisory board participation for AstraZeneca and Chiesi (all paid to his institution). R.B. has received grants and personal fees from Boehringer Ingelheim, GlaxoSmithKline, Novartis and Roche, and personal fees from AstraZeneca, Chiesi, Cipla and Teva.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}